Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
| 29.1 | |
| 28.1 | |
| - | |
| 29.47 | |
| 28.02 | |
| 18.82-45.58 | |
| 4 064 M | |
| 146 M | |
| 0 | |
| -0.52 | |
| 0.713 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with...
Dianthus Therapeutics DNTH is a clinical-stage company, developing next-generation complement therapies to treat severe autoimmune diseases. Its lead investigational candidate is DNTH103, which is be...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
